Hyderabad, India, October 29, 2008: The Orissa Government has selected Bharat Biotech International (BBIL), www.bharatbiotech.com the multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics as the ‘Developer’ for its first Public-Private-Partnership (PPP) “Biotech Pharma IT” project in the state. The park to be located at Mouza-Andharua, Bhubaneswar is estimated to cost about Rs.100 crores and it is slated to be completed in 8 years.
The State Government of Orissa has allocated 54.86 acres of land to Bharat Biotech towards the development of an integrated industrial park to attract and promote pharmaceutical, biotechnology and information technology industries in Bhubaneswar in the Private Public Partnership mode. The Park is the first of its kind in Orissa envisages promotion of Biotech, Pharmaceuticals and IT industries in the State.
Making the announcement Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech International, said “We are delighted that the Government of Orissa has acknowledged our competence and awarded this prestigious project to BBIL. Our task is to focus on rapid development of this park by developing core infrastructure and technology to enable establishment of new companies whereby new local Entrepreneurs in the Biotechnology field will be created.”
Within this Park another 10 acre will be developed to house a Biotechnology Incubation Centre for use by researchers, entrepreneurs and students. The Department of Biotechnology, Govt of India, has assured funding for the equipment/instrumentation of this center of excellence within the park and Bharat Biotech will provide the necessary building infrastructure.
The development of this integrated park would help kick start investments in the areas of biotechnology and pharmaceuticals in Orissa. The land has been allocated in the form of a long term lease to Bharat Biotech with commitments of time bound development of infrastructure and facilities.
Bharat Biotech has significant prior experience in the development and successful commercialization of technology parks in India. Dr. Krishna Ella and his team have successfully developed an integrated food biotech park in Bangalore. Dr. Ella was also instrumental in the establishment and development of the Genome Valley BioPharmaceutical cluster located in the outskirts of Hyderabad.
Bharat Biotech will form a Special Purpose Vehicle (SPV) to develop the BT-Pharma-IT Park at Andharua. The SPV will execute the Lease cum Development Agreement of the Bharat Biotech with Orissa Industrial Infrastructure Development Corporation (IDCO). The State Govt of Orissa and IDCO have agreed to provide all external infrastructure facilities, such as road connectivity, water supply, power supply with 33 KVA sub-station etc to facilitate rapid development of internal infrastructure.
About Bharat Biotech
Bharat Biotech International Limited, Hyderabad, India, is a multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Bharat Biotech was established in the year 1996, is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research. Bharat Biotech is the first bio-Pharma facilities in India to be audited and approved by Korean Food & Drugs Administration (KFDA).
Bharat Biotech sprawls over a picturesque campus at Genome Valley, Hyderabad, built with an investment of over USD 100 million, the facility’s manufacturing, control procedures and protocols, conform to the stringent standards laid down by internationally recognized institutions such as USFDA, UKMCA and WHO. Bharat has set new benchmarks in Innovation and Quality that epitomizes the tremendous progress of Indian biotechnology in the global arena.
Bharat Biotech is the first to manufacture, INDIKINASE™, a recombinant Streptokinase and BIOGIT™, a yeast based probiotic yeast product in India. Bharat Biotech has commercialized India’s first recombinant Epidermal Growth Factor, REGEN-D™ to combat diabetic foot ulcers, burns. Bharat Biotech has a strong pipeline of vaccines to combat Malaria, Rotavirus and Japanese Encephalitis infections.